Global Orphan Drugs Market: Snapshot
During the 2017-2025 forecast period, the global orphan drugs market is expected to display a healthy growth rate, backed by a number of factors such as high return on investments for the development of orphan drugs, strong research and development initiatives for orphan drugs in developed countries, and increasing number of rare diseases related to genetic mutations that are treated using orphan drugs.
In matters of competition, players in the moderately fragmented global orphan drugs market are focused on strategic acquisitions, and are focused to leverage incentives offered by governments for efforts for R&D of orphan drugs.
A report by Transparency Market Research estimates the global orphan drugs market will expand at a healthy 12.1% CAGR between 2017 and 2025, for the market to be valued at US$318.5 bn by the end of 2025.
Increasing Number of Rare Cancer Cases Stokes Growth of Oncology Disease Type Segment
The report studies the global orphan drugs market on the basis of disease type, product type, distribution channel, and geography. The segments of this market depending upon disease type are oncology, gastrointestinal, pulmonary, neurology, hematology, cardiovascular, metabolic disorders, endocrinology, infectious diseases, and others. Of them, in 2016, oncology led the market vis-à-vis revenue, and the segment is expected to hold on to its dominant position until the end of 2025. The strong growth of oncology disease type segment is mainly because of increasing drug approvals for treatment of rare cancers. In the European Union, for instance, the burden of cancer has been growing significantly, with 22% of all diagnosed cancer cases identified as rare cancers. The segment of metabolic disorders is expected to expand at a significant CAGR over the forecast period. The increasing number of urea cycle disorders that form a significant part of metabolic disorders account for the high growth of metabolic disorders segment.
In terms of product type, the report divides the global orphan drugs market into biologic and non-biologic products. Vis-à-vis revenue, biologic products led the market in 2016 and is anticipated to stay dominant over the report’s forecast period. Further, the segment of biologic products is expected to display a significant CAGR over the forecast period mainly because of high efficacy of biologic products for treatment of diseases, fewer side effects, and difficulty to develop generic versions of these drugs.
On the basis of distribution channel, the global orphan drugs market has been segmented into hospital pharmacies, retail pharmacies, specialty pharmacies, and others. Hospital pharmacies led the overall market in 2016 on the basis of revenue, and the trend is anticipated to continue over the forecast period. Moreover, increasing hospitalization for the treatment of rare diseases, ease of availability of products in hospital pharmacies, and increasing referrals from physicians for hospitalization are aiding growth of the hospital distribution channel.
Meticulous Efforts for R&D of Orphan Drugs Makes North America Leader
Geography-wise, the global orphan drugs market is segregated into North America, Europe, and Rest of the World. In 2016, North America held the leading share of the market due to various factors that include a well-established healthcare infrastructure, favorable regulations for the approval of drugs for rare diseases, drug exclusivity status received by orphan drugs, and initiatives by governmental and non-governmental agencies to raise awareness about use of orphan drugs for treatment of rare diseases. Within North America, the U.S. contributes substantially to the orphan drugs market as more than 30 million people are reported to suffer from rare diseases in the country. This calls for strong R&D for development of orphan drugs.
Prominent names in the orphan drugs market include Novartis AG, Celgene Corporation, Pfizer Inc., Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Eisai Co. Ltd., Bayer AG, Merck & Co. Inc., Biogen Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Eli Lilly and Company, AstraZeneca plc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., Johnson & Johnson, and Shire plc. among others.
Global Orphan Drugs Market: Overview
Orphan diseases can be defined as the medical conditions which impacts a small group of the population and are mostly genetic in nature. For the treatment of these rare diseases pharmaceutical agents are specifically developed which are known as orphan drugs. The market for these orphan drugs is anticipated to grow significantly in the forecast period, owing to the rising prevalence of rare diseases, focus of government and non-government organizations on creating awareness, research and development grants, and fee waivers and tax credits offered, among others.
Global Orphan Drugs Market: Research Methodology
The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of drugs employed in the treatment of rare diseases in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Bn for disease type, product type, distribution channel, and geography for the period 2015 to 2025, considering the macro and micro environmental factors. The revenue generated from each disease type, product type, and distribution channel was calculated by considering the prevalence of rare diseases, orphan drug approvals, regulatory procedures, and the awareness of orphan diseases across all the geographies.
The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on disease type, product type, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the nurse call systems market in the current and future scenario. The report also provides Porter’s five forces analysis, the acquisitions timeline of orphan drug companies, SWOT analysis of the market, regulatory scenario, comparative analysis of orphan drug policies, rare diseases prevalence, pricing scenario of the orphan drugs, major selling orphan drugs, and drug exclusivity of certain of the orphan drugs, for the market.
Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The study also covers detailed country analysis contributing majorly in the nurse call systems market.
Global Orphan Drugs Market: Competitive Landscape
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the nurse call systems market report are Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Biogen, Inc., Shire plc, and Amgen, Inc., among others.
The Orphan Drugs Market has been segmented as follows:
- Orphan Drugs Market, by Disease Type, Revenue (US$ Bn) 2015-2025
- Metabolic disorders
- Infectious diseases
- Orphan Drugs Market, by Product Type, Revenue (US$ Bn) 2015-2025
- Orphan Drugs Market, by Distribution Channel, Revenue (US$ Bn) 2015-2025
- Hospital Pharmacies
- Speciality Pharmacies
- Retail pharmacies
- Orphan Drugs Market Revenue, by Geography (US$ Bn), 2015-2025
- North America
- Rest of Europe
- Rest of the World
- South Korea
- North America